Zeneca Nolvadex (tamoxifen) patent upheld, enjoining Novopharm ANDA application.
Executive Summary
ZENECA NOLVADEX PATENT UPHELD IN SUIT AGAINST NOVOPHARM by Baltimore federal court Judge Frederic Smalkin April 29. Zeneca began patent infringement proceedings against the Canadian generic pharmaceutical manufacturer Novopharm in January 1995, following Novopharm's ANDA application for tamoxifen citrate. Novopharm can appeal the ruling to the federal circuit appeals court. Zeneca claims that the patent for the breast cancer treatment runs through August 2002.